EGFR exon 20 alterations in non-small cell lung cancer (NSCLC) present a formidable treatment challenge due to their limited therapeutic options and resistance to several tyrosine kinase inhibitors (TKIs). Here, EGFR is linked to non-small cell lung carcinoma.